Skip to main content
    E

    Enlivex Therapeutics Ltd (ENLV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.10
    -0.09 (-7.56%)

    Market Cap: $1.82M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Enlivex Therapeutics Ltd (ENLV) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Enlivex Therapeutics are Purple Biotech (PPBT), Revelation Biosciences (REVB) and XTL Biopharmaceuticals Ltd ADR (XTLB). By market cap, Enlivex Therapeutics ranks 9th of the 13 companies on this page; Liminatus Pharma, Inc. Class A Common Stock (LIMN) is the largest at $4.02M.

    Peer Comparison

    ENLV's ROIC of -0.3% is above the peer median of -156.2%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Enlivex Therapeutics (ENLV)$1.82MN/AN/A0.0%-0.3%0.0%0.00%
    Purple Biotech (PPBT)$2.65MN/AN/A0.0%-156.2%0.0%0.00%
    Revelation Biosciences Inc (REVB)$2.43MN/AN/A0.0%N/A0.0%0.00%
    XTL Biopharmaceuticals Ltd ADR (XTLB)$3.93MN/A4.0x0.0%N/A0.0%0.00%
    Calidi Biotherapeutics Inc. (CLDI)$2.29MN/AN/A0.0%N/A0.0%0.00%
    Ernexa Therapeutics Inc. (ERNA)$2.84MN/AN/A0.0%N/A-94.1%0.00%
    XORTX Therapeutics Inc (XRTX)$2.00MN/AN/A0.0%N/A0.0%0.00%
    Kairos Pharma, Ltd. (KAPA)$1.54MN/AN/A0.0%N/A0.0%0.00%
    Genprex Inc (GNPX)$1.71MN/AN/A0.0%N/A0.0%0.00%
    Scinai Immunotherapeutics Ltd (SCNI)$1.05MN/AN/A-80.1%N/A572.0%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    VivoSim Labs, Inc. (VIVS)$2.58MN/A15.1x0.0%N/A-51.4%0.00%
    HCW Biologics Inc (HCWB)$1.73MN/A0.2x-83.1%-51.6%1970.0%0.00%
    Peer median$2.36MN/A4.0x0.0%-156.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Enlivex Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Purple Biotech (PPBT)
    Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United...
    PPBT competitors
    Revelation Biosciences Inc (REVB)
    Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics...
    REVB competitors
    XTL Biopharmaceuticals Ltd ADR (XTLB)
    XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment...
    Calidi Biotherapeutics Inc. (CLDI)
    Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.
    CLDI competitors
    Ernexa Therapeutics Inc. (ERNA)
    Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients.
    ERNA competitors
    XORTX Therapeutics Inc (XRTX)
    XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease...
    XRTX competitors
    Kairos Pharma, Ltd. (KAPA)
    Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients.
    KAPA competitors
    Genprex Inc (GNPX)
    Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
    GNPX competitors
    Scinai Immunotherapeutics Ltd (SCNI)
    Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune...
    SCNI competitors
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors
    VivoSim Labs, Inc. (VIVS)
    VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease.
    VIVS competitors
    HCW Biologics Inc (HCWB)
    HCW Biologics Inc is a forward-thinking biotechnology company focused on pioneering immunotherapies and vaccine technologies to tackle pressing health issues...
    HCWB competitors

    Frequently Asked Questions About ENLV

    Who are Enlivex Therapeutics' main competitors?

    The companies most similar to Enlivex Therapeutics include Purple Biotech (PPBT), Revelation Biosciences (REVB), XTL Biopharmaceuticals Ltd ADR (XTLB), Calidi Biotherapeutics (CLDI) and Ernexa Therapeutics (ERNA), listed from the closest match.

    Who is Enlivex Therapeutics' biggest competitor?

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) is the largest of the similar companies at $4.02M; Purple Biotech (PPBT) is the closest match by business profile, size, sector and industry.

    How does ENLV stock compare with its competitors?

    ENLV's net margin is 0.0% against a peer median of 0.0%.

    Which of Enlivex Therapeutics' competitors pays a higher dividend?

    Enlivex Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Enlivex Therapeutics bigger than its competitors?

    No. Enlivex Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Liminatus Pharma, Inc. Class A Common Stock (LIMN) at $4.02M.